The short version of REV-ERB agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-26 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
Deupsilocin (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; former developmental code names HLP003 and CYB0003), also known as deuterated psilocin or as psilocin-d10, is a psychedelic drug of the tryptamine family related to psilocin which is under development for the treatment of major depressive disorder, alcoholism, and other psychiatric disorders. It is taken orally. The drug is a deuterated isotopologue of psilocin with altered pharmacokinetics.
. R is the gas constant and T is the absolute temperature. Note that pKa = −log(Ka) and 2.303 ≈ ln(10). At 25 °C, ΔG⊖ in kJ·mol−1 ≈ 5.708 pKa (1 kJ·mol−1 = 1000 joules per mole). Free energy is made up of an enthalpy term and an entropy term.
Today, the "exteroceptors" are the organs that provide information originating outside the body, such as the eyes, ears, mouth, and skin. The interoceptors provide information about the internal organs, and the "proprioceptors" provide information about movement derived from muscular, tendon, and articular sources. Using Sherrington's system, physiologists and anatomists search for specialised nerve endings that transmit mechanical data on joint capsule, tendon and muscle tension (such as Golgi tendon organs and muscle spindles), which play a large role in proprioception. Primary endings of muscle spindles "respond to the size of a muscle length change and its speed" and "contribute both to the sense of limb position and movement". Secondary endings of muscle spindles detect changes in muscle length, and thus supply information regarding only the sense of position. Essentially, muscle spindles are stretch receptors. It has been accepted that cutaneous receptors also contribute directly to proprioception by providing "accurate perceptual information about joint position and movement", and this knowledge is combined with information from the muscle spindles.
Sources: en.wikipedia.org
== Pathophysiology == SJS is a type IV hypersensitivity reaction in which a drug or its metabolite stimulates cytotoxic T cells (i.e. CD8+ T cells) and T helper cells (i.e. CD4+ T cells) to initiate autoimmune reactions that attack self tissues. In particular, it is a type IV, subtype IVc, delayed hypersensitivity reaction dependent in part on the tissue-injuring actions of natural killer cells. This contrasts with the other types of SCARs disorders, i.e., the DRESS syndrome which is a Type IV, Subtype IVb, hypersensitivity drug reaction dependent in part on the tissue-injuring actions of eosinophils and acute generalized exanthematous pustulosis which is a Type IV, subtype IVd, hypersensitivity reaction dependent in part on the tissue-injuring actions of neutrophils. Like other SCARs-inducing drugs, SJS-inducing drugs or their metabolites stimulate CD8+ T cells or CD4+ T cells to initiate autoimmune responses. Studies indicate that the mechanism by which a drug or its metabolites accomplishes this involves subverting the antigen presentation pathways of the innate immune system. The drug or metabolite covalently binds with a host protein to form a non-self, drug-related epitope. An antigen presenting cell (APC) takes up these alter proteins; digests them into small peptides; places the peptides in a groove on the human leukocyte antigen (i.e. HLA) component of their major histocompatibility complex (i.e. MHC); and presents the MHC-associated peptides to T-cell receptors on CD8+ T cells or CD4+ T cells.
== History == The first isolation and structure identifications of prednisone and prednisolone were done in 1950 by Arthur Nobile. The first commercially feasible synthesis of prednisone was carried out in 1955 in the laboratories of Schering Corporation, which later became Schering-Plough Corporation, by Arthur Nobile and coworkers. They discovered that cortisone could be microbiologically oxidized to prednisone by the bacterium Corynebacterium simplex. The same process was used to prepare prednisolone from hydrocortisone. The enhanced adrenocorticoid activity of these compounds over cortisone and hydrocortisone was demonstrated in mice. Prednisone and prednisolone were introduced in 1955 by Schering and Upjohn, under the brand names Meticorten and Delta-Cortef, respectively.
Chinese cuisine is deeply intertwined with traditional Chinese medicine, such as in the practise of Chinese food therapy. Color, scent and taste are the three traditional aspects used to describe Chinese food, as well as the meaning, appearance, and nutrition of the food. Cooking should be appraised with respect to the ingredients used, knife work, cooking time, and seasoning.
Sources: en.wikipedia.org
The MNHN was formally established on June 10, 1793, by the French Convention, the government during the French Revolution, at the same time that it established the Louvre Museum. But its origins went back much further, to the Royal Garden of Medicinal Plants, which was created by King Louis XIII in 1635, and was directed and run by the royal physicians. A royal proclamation of the boy-king Louis XV on 31 March 1718, removed the purely medical function. Besides growing and studying plants useful for health, the royal garden offered public lectures on botany, chemistry, and comparative anatomy. In 1729, the chateau in the garden was enlarged with an upper floor, and transformed into the cabinet of natural history, designed for the royal collections of zoology and mineralogy. A series of greenhouses were constructed on the west side of the garden, to study the plants and animals collected by French explorers for their for medical and commercial uses. From 1739 until 1788, the garden was under the direction of Georges-Louis Leclerc, Comte de Buffon, one of the leading naturalists of the Enlightenment. Though he did not go on scientific expeditions himself, he wrote a monumental and influential work, "Natural History", in thirty-six volumes, published between 1749 and 1788. In his books, he challenged the traditional religious ideas that nature had not changed since the creation; he suggested that the earth was seventy-five thousand years old, divided into seven periods, with man arriving in the most recent.
== Notable isotopes == Plutonium-238 has a half-life of 87.74 years and emits alpha particles. Pure 238Pu for radioisotope thermoelectric generators that power some spacecraft is produced by neutron capture on neptunium-237 but plutonium from spent nuclear fuel can contain as much as a few percent 238Pu, originating from 237Np, alpha decay of 242Cm, or (n,2n) reactions. Plutonium-239 has half-life 24,100 years. 239Pu and 241Pu are fissile; meaning their nuclei can split by being bombarded by slow thermal neutrons, releasing energy, gamma radiation and more neutrons. It can therefore sustain a nuclear chain reaction, leading to applications in nuclear weapons and nuclear reactors. 239Pu is synthesized by irradiating uranium-238 with neutrons in a nuclear reactor, then recovered via nuclear reprocessing of the fuel. Further neutron capture produces successively heavier isotopes. Plutonium-240 has a high rate of spontaneous fission, raising the background neutron radiation of plutonium. Plutonium is graded by proportion of 240Pu: weapons grade (<7%), fuel grade (7–19%) and reactor grade (>19%). Lower grades are less suited for bombs and thermal reactors but can fuel fast reactors. Plutonium-241 is fissile, but beta decays with a half-life of 14 years to americium-241. Plutonium-242 is not fissile, nor very fertile (requiring 3 more neutron captures to become fissile); and has a low neutron capture cross section, and a longer half-life than any of the lighter isotopes. Plutonium-244 is the most stable isotope of plutonium, with a half-life of about 80 million years.
In terms of the effects of progestogens on sex drive, one study assessed the use of dydrogesterone to improve sexual desire in transgender women and found no benefit. Another study likewise found that oral progesterone did not improve sexual function in cisgender women. Progestogens can have adverse effects. Oral progesterone has inhibitory neurosteroid effects and can produce side effects such as sedation, mood changes, and alcohol-like effects. Many progestins have off-target activity, such as androgenic, antiandrogenic, glucocorticoid, and antimineralocorticoid activity, and these activities likewise can contribute unwanted side effects. Furthermore, the addition of a progestin to estrogen therapy has been found to increase the risk of blood clots, cardiovascular disease (e.g., coronary heart disease and stroke), and breast cancer compared to estrogen therapy alone in postmenopausal women. Although it is unknown if these health risks of progestins occur in transgender women similarly, it cannot be ruled out that they do. High-dose progestins increase the risk of benign brain tumors including prolactinomas and meningiomas as well. Because of their potential detrimental effects and lack of supported benefits, some researchers have argued that, aside from the purpose of testosterone suppression, progestogens should not generally be used or advocated in transgender women or should only be used for a limited duration (e.g., 2–3 years).
=== Politics === Though considered a political backwater of the federation for much of the 50s and 60s, the 70s saw the ascension of a strong Bosnian political elite. While working within the communist system, politicians such as Džemal Bijedić, Branko Mikulić and Hamdija Pozderac reinforced and protected the sovereignty of Bosnia and Herzegovina. Their efforts proved key during the turbulent period following Tito's death in 1980, and are today considered some of the early steps towards Bosnian independence. However, the republic hardly escaped the increasingly nationalistic climate of the time unscathed. Following the death of Tito in 1980, rising nationalist ideas primarily noted in Serbian academia, pressured Bosnia to deal with allegations of rising nationalism in their own society. One of the most controversial events that were taken by a Bosnian political leadership was a so-called Sarajevo process in 1983 where, under significant pressure from Serbia's political leadership, Bosnian political elite used their influence to secure convictions for several Bosniak nationalists as a type of a political sacrifice to gain political points in the fight against Serbian nationalists. The Sarajevo process centered on convicting Alija Izetbegović for writing "The Islamic Declaration", a literary work which was in the Yugoslav communist regime considered a radical approach towards socialist ideals of former Yugoslavia that were based on suppression of nationalism and any violation of that doctrine was punishable by law.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.